REG - GlaxoSmithKline PLC - GSK response to SFO Statement

GSKAnnouncement

22/02/2019 11:25

RNS Number : 8883Q
GlaxoSmithKline PLC
22 February 2019
 


 
Issued: 22 February 2019, London UK - LSE Announcement
 
GSK response to SFO Statement
 
 
In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.
 
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
 
 



GSK enquiries:
















UK Media enquiries:


Simon Steel


+44 (0) 20 8047 5502


(London)








Tim Foley


+44 (0) 20 8047 5502


(London)




Analyst/Investor enquiries:


Sarah Elton-Farr


+44 (0) 208 047 5194


(London)








Jeff McLaughlin


+1 215 751 7002


(Philadelphia)



 



Cautionary statements regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.
 
 
 




 
 
Registered in England & Wales:
No. 3888792


 








 




Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS


 



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RSPEAFAAAFKNEFF